Sun et al. developed ROTACs, a type of PROTAC that targets and degrades specific signaling molecules, using a chimera called R2PD1 to efficiently degrade PD-L1 in melanoma cells, outperforming existing treatments in activating immune responses and inhibiting tumor growth [166]. Here, CD274 is linked to neoplasm.